Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DARÉ BIOSCIENCE, INC.

(DARE)
  Report
Real-time Estimate Cboe BZX  -  10:10 2022-11-28 am EST
0.9350 USD   -0.53%
11/16Dare Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health
AQ
11/15Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health
AQ
11/14Dare Bioscience, Inc. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Days
:
Hours
:
Minutes
:
Seconds
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/21/2022 11/22/2022 11/23/2022 11/25/2022 11/28/2022 Date
0.9402(c) 0.925(c) 0.9282(c) 0.94(c) 0.94 Last
431 191 111 634 108 304 32 199 21 230 Volume
-2.06% -1.62% +0.35% +1.27% 0.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 15,3 M - -
Net income 2022 -17,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,48x
Yield 2022 -
Sales 2023 14,0 M - -
Net income 2023 -28,3 M - -
Net Debt 2023 - - -
P/E ratio 2023 -3,20x
Yield 2023 -
Capitalization 79,7 M 79,7 M -
Capi. / Sales 2022 5,20x
Capi. / Sales 2023 5,70x
Nbr of Employees 24
Free-Float 98,0%
More Financials
Company
Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing products for women’s health. Its portfolio of differentiated therapies expands treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Its product pipeline includes three product candidates in advanced stages... 
More about the company
Ratings of Daré Bioscience, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about DARÉ BIOSCIENCE, INC.
11/16Dare Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of L..
AQ
11/15Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of L..
AQ
11/14Dare Bioscience, Inc. : Regulation FD Disclosure, Other Events, Financial Statements and E..
AQ
11/14Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical St..
AQ
11/14Daré Bioscience, Inc. Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clini..
CI
11/10Transcript : Daré Bioscience, Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10DARE BIOSCIENCE, INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
11/10Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months En..
CI
11/10Earnings Flash (DARE) DARE BIOSCIENCE Reports Q3 Loss $-0.08
MT
11/10Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Upd..
AQ
11/08Daré Bioscience to Present at the Stifel 2022 Healthcare Conference
AQ
11/03Dare Bioscience, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
11/03Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Confere..
AQ
11/01Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cr..
AQ
11/01Daré Bioscience Announces Subject Screening for Phase 2B Respond Study of Sildenafil Cr..
CI
More news
News in other languages on DARÉ BIOSCIENCE, INC.
11/14Daré Bioscience, Inc. annonce les premiers résultats positifs de l'étude clinique de ph..
11/10Daré Bioscience, Inc. annonce ses résultats pour le troisième trimestre et les neuf moi..
11/01Daré Bioscience annonce que le dépistage des sujets pour l'étude de réponse de phase 2B..
10/17Dare Bioscience affirme que l'anneau vaginal a amélioré certains symptômes de la ménopa..
10/17Daré annonce les principaux résultats de son étude clinique de phase 1/2 sur Dare-HRT1
More news
Analyst Recommendations on DARÉ BIOSCIENCE, INC.
More recommendations
ETFs positioned on DARÉ BIOSCIENCE, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares Micro-Cap ETF - USD0.02%0.71%United_States
More ETFs positioned on DARÉ BIOSCIENCE, INC.
Chart DARÉ BIOSCIENCE, INC.
Duration : Period :
Daré Bioscience, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DARÉ BIOSCIENCE, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 0,94 $
Average target price 5,33 $
Spread / Average Target 467%
EPS Revisions
Managers and Directors
Sabrina Martucci Johnson President, CEO, Secretary & Director
Lisa Walters-Hoffert Chief Financial Officer
William H. Rastetter Chairman
David Friend Chief Scientific Officer
Christine Mauck Medical Director
Sector and Competitors
1st jan.Capi. (M$)
DARÉ BIOSCIENCE, INC.-53.00%80
MODERNA, INC.-30.55%67 769
IQVIA HOLDINGS INC.-22.03%40 859
LONZA GROUP AG-33.93%39 445
ALNYLAM PHARMACEUTICALS, INC.25.44%26 171
SEAGEN INC.-20.16%22 918